



## **IMMUSOFT FINISHES FIRST CLOSING ON OVERSUBSCRIBED \$3 MILLION ROUND**

**SEATTLE, Wash.** (November 1, 2016)— Immusoft Corporation, a Seattle, Wash.-based gene therapy company, has closed on \$2.74 million of a \$3 million fundraising round. Founders Fund’s FF Science and Technium Partners led the investment.

The round was oversubscribed and Immusoft says it expects to close on the remaining amount shortly.

“The capital raised in this round will give us the resources we need to submit our Investigational New Drug application,” says Matthew Scholz, Founder and CEO of Immusoft. “We are grateful to our investors and for the speed in which we were able to close our latest effort to raise capital.”

Scholz says Immusoft continues to explore working with potential partners. The money raised in this round, he says, positions the company well as it moves forward with clinical and business operations and to its Series B.

Immusoft has developed a way to use a patient’s immune cells to cure disease. Its Immune System Programming (ISP™) technology reprograms patient B cells to treat diseases.

### **About Immusoft**

*Immusoft Corporation’s (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™). The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP™ become miniature drug factories that are expected to survive in patients for many years. Founded in 2009, Immusoft is based in Seattle, Wash.*

###